Medicine composition for treating vaginitis and preparation method and application thereof

A composition and technology for vaginitis, applied in the field of biomedicine, can solve the problems of hindering hEGF transdermal absorption and inability to repair vaginal mucosal tissue, achieve good therapeutic effect, short treatment time, and prevent infection

Inactive Publication Date: 2016-05-04
FUJIAN LONGSHENG BIOLOGICAL TECH CO LTD
View PDF5 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, in the process of inflammation treatment, once the mucosal barrier is formed, it hinders the transderma

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine composition for treating vaginitis and preparation method and application thereof
  • Medicine composition for treating vaginitis and preparation method and application thereof
  • Medicine composition for treating vaginitis and preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1-6

[0038] The preparation of the pharmaceutical composition of embodiment 1-6 treatment vaginitis

[0039] The formula of the pharmaceutical composition for the treatment of vaginitis of the present embodiment is as shown in the following table 1:

[0040] Table 1 treats the prescription of the pharmaceutical composition of vaginitis

[0041]

[0042]

[0043] According to the formula shown in table 1, the gel preparation for external use is prepared through the following steps:

[0044] A. Prepare the raw materials and auxiliary materials according to the dosage in Table 1, and set them aside;

[0045] B. Preparation of solution matrix:

[0046] Add the carbomer 940 and glycerol in step A into the container, add deionized water, stir and mix well, sterilize under high temperature and high pressure, take it out, cool down, and set aside;

[0047] C. Dissolve nano-silver or miconazole nitrate in glycerol, and put it into the matrix and stir and mix rapidly;

[0048] D. A...

Embodiment 7

[0052] Example 7 Experimental method for the therapeutic effect of Candida albicans on vaginitis model animals

[0053] 1. Vaginitis model preparation

[0054] (1) Bilateral ovariectomy of model rats: Except for the normal group, the rats in the other groups were fasted for 16-17 hours, anesthetized by intraperitoneal injection of pentobarbital sodium 35 mg / kg, and removed under aseptic conditions. Lateral ovary. Subcutaneous injection of penicillin 100,000 u / piece after operation, once a day for 3 consecutive days, to prevent infection. From the 4th day after the operation, vaginal smears were performed one by one. For 3 consecutive days, no vaginal epithelial keratinocytes were found, and all the model rats were in estrus, which proved that the ovariectomy was complete.

[0055] (2) Create false estrus, resulting in low immune function: subcutaneous injection of diethylstilbestrol 2 mg / kg, once a day, for 4 consecutive days, on the 7th day after operation, vaginal smear ex...

Embodiment 8

[0067] Example 8 transdermal EGF combined with nano-silver for the treatment of vaginitis

[0068] 1. Effect of drugs on serum IL-1 content of vaginitis model rats

[0069] The amount of interleukin 1 (IL-1) in the body determines the level of inflammation. By detecting the level of IL-1 blocked by the rat vagina, the results in Table 3 show that the serum IL-1 content of the model control group increased significantly, and there was a significant difference (P0.05); under equal doses (P>0.05), see Table 3 and figure 1 .

[0070] The influence of table 3 medicine on serum IL-1 content of vaginitis model rat

[0071]

[0072] Note: Comparing the model group with the normal group, ##P<0.01; comparing each drug group with the model group *P<0.05, **P<0.01

[0073] (1) (3) (4) (5) (6) represent embodiment 1, 3, 4, 5, 6 respectively.

[0074] 2. The effect of drugs on the index of vaginal organs in vaginitis model rats

[0075] After the research on the vaginal viscera in...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a medicine composition for treating vaginitis. The medicine composition is prepared from transdermal EGF and antibacterial drugs which serve as raw materials and carbomer and glycerol which serve as auxiliary materials. The invention further discloses a preparation method of the medicine composition. The preparation method comprises the following steps of preparing the raw materials and the auxiliary materials; compounding a solution matrix; dissolving nano-silver or miconazole nitrate in glycerol; adding triethanolamine to the matrix, and stirring the mixture slowly till the matrix becomes gel; conducting filtration and sterilization on the transdermal EGF; adding a transdermal EGF solution obtained after filtration to the gel matrix, adding deionized water, and conducting sub packaging. The medicine composition obtained through the method can be widely applied to externalia infection such as bacterial vaginitis and acroposthitis, restoration and healing of skin mucous membranes are accelerated in the inflammation treatment process, bacterial superinfection is prevented, and a certain auxiliary effect is achieved for vaginal contraction.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and in particular relates to a pharmaceutical composition for treating vaginitis, a preparation method and application thereof. Background technique [0002] Bacterial vaginosis is a relatively common gynecological inflammation, including fungal vaginitis and candidal vaginitis, mainly caused by bacterial infection. Common symptoms include pruritus, vulvar erythema, abnormal leucorrhea, etc., which seriously cause redness and swelling of vaginal mucosa and ulcers, which bring serious pain to patients. The current treatment for bacterial vaginosis is mainly through topical antifungal drugs. Such as nano-silver, miconazole nitrate or traditional Chinese medicine ingredients such as matrine and Phellodendri extract. The effect is obvious in a short period of time when using antibacterial drugs to treat vaginitis, but after stopping the drugs, a considerable proportion of patients will relapse....

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K38/18A61K45/06A61K31/4174A61K33/38A61K9/06A61K47/10A61K47/32A61P15/02A61P31/04A61P31/10
CPCA61K38/1808A61K9/0034A61K9/06A61K31/4174A61K33/38A61K45/06A61K47/10A61K47/32A61K2300/00
Inventor 饶照明阮仁全温龙平陈明魏鹏飞张云娇
Owner FUJIAN LONGSHENG BIOLOGICAL TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap